Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Pitching Cormorant Asset Management? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room